חוב לטווח קצר להון DBV Technologies (DBVT)

DBV Technologies S.A. (DBVT) revenues are based on the implementation of immunotherapy, where the commercialization of Viaskin Peanut patches for treating childhood allergies will serve as the key growth driver. This chart confirms the asset's price action, with a value of 0.10. The innovative method of skin-based immune training replaces injections, representing a breakthrough in pediatrics. Meanwhile, the company strictly adheres to biomaterial disposal regulations within its laboratories.

This ratio compares the volume of liabilities with a maturity of up to one year against the amount of equity. This proportion reveals the risk of cash flow gaps and the company's dependence on short-term borrowing during periods of volatility. For DBV Technologies S.A. (DBVT), this is critical when financing the regulatory processes for bringing non-invasive patches to market. The dynamics of the short-term debt to equity ratio reflect the balance between financial stability and the speed of expansion within the immunotherapy niche.